Literature DB >> 11703960

Frequency of serum low-density lipoprotein cholesterol measurement and frequency of results < or=100 mg/dl among patients who had coronary events (Northwest VA Network Study).

K L Sloan1, A E Sales, J P Willems, N R Every, G V Martin, H Sun, S Pineros, N Sharp.   

Abstract

This population-based, cross-sectional analysis targeted all veterans with coronary heart disease (CHD) who were active patients in primary care or cardiology clinics in the Veterans Health Administration Northwest Network from July 1998 to June 1999. We report guideline compliance rates, including whether low-density lipoprotein (LDL) was measured, and if measured, whether the LDL was < or=100 mg/dl. In addition, we utilized multivariate logistic regression to determine patient characteristics associated with LDL measurements and levels. Of 13,891 active patients with CHD, 5,552 (40.0%) did not have a current LDL measurement. Of those with LDL measurements, 39.1% were at the LDL goal of < or =100 mg/dl, whereas 26.5% had LDL > or =130 mg/dl. Male gender, younger age, history of angioplasty or coronary artery bypass grafting, current hypertension, diabetes mellitus, and angina pectoris were associated with increased likelihood of LDL measurement. Older age and current diabetes and angina were associated with increased likelihood of LDL being < or =100 mg/dl, if measured. Although these rates of guideline adherence in the CHD population compare well to previously published results, they continue to be unacceptably low for optimal clinical outcomes. Attention to both LDL measurement and treatment (if elevated) is warranted.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11703960     DOI: 10.1016/s0002-9149(01)02050-1

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  6 in total

Review 1.  Identifying neck and back pain in administrative data: defining the right cohort.

Authors:  Patricia L Sinnott; Andrew M Siroka; Andrea C Shane; Jodie A Trafton; Todd H Wagner
Journal:  Spine (Phila Pa 1976)       Date:  2012-05-01       Impact factor: 3.468

2.  A trial of education, prompts, and opinion leaders to improve prescription of lipid modifying therapy by primary care physicians for patients with ischemic heart disease.

Authors:  H E Bloomfield; D B Nelson; M van Ryn; B J Neil; N J Koets; J N Basile; F F Samaha; R Kaul; J L Mehta; D Bouland
Journal:  Qual Saf Health Care       Date:  2005-08

3.  Practice patterns in NAFLD and NASH: real life differs from published guidelines.

Authors:  Mary E Rinella; Zurabi Lominadze; Rohit Loomba; Michael Charlton; Brent A Neuschwander-Tetri; Stephen H Caldwell; Kris Kowdley; Stephen A Harrison
Journal:  Therap Adv Gastroenterol       Date:  2016-01       Impact factor: 4.409

Review 4.  Review of evidence and explanations for suboptimal screening and treatment of dyslipidemia in women. A conceptual model.

Authors:  Catherine Kim; Timothy P Hofer; Eve A Kerr
Journal:  J Gen Intern Med       Date:  2003-10       Impact factor: 5.128

5.  The association between processes, structures and outcomes of secondary prevention care among VA ischemic heart disease patients.

Authors:  P Michael Ho; Allan V Prochazka; David J Magid; Anne E Sales; Gary K Grunwald; Karl E Hammermeister; John S Rumsfeld
Journal:  BMC Cardiovasc Disord       Date:  2006-02-09       Impact factor: 2.298

6.  Implementing electronic clinical reminders for lipid management in patients with ischemic heart disease in the veterans health administration: QUERI Series.

Authors:  Anne Sales; Christian Helfrich; P Michael Ho; Ashley Hedeen; Mary E Plomondon; Yu-Fang Li; Alison Connors; John S Rumsfeld
Journal:  Implement Sci       Date:  2008-05-29       Impact factor: 7.327

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.